[{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Nanogen Pharmaceutical Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Nanocovax","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Nanogen Pharmaceutical Biotechnology","highestDevelopmentStatusID":"10","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Nanogen Pharmaceutical Biotechnology"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Peginterferon Alfa-2a","moa":"Interferon alpha\/beta receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"11","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Vietstar Biomedical Research | MedProve","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"VIETNAM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Trastazumab","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | MedProve","highestDevelopmentStatusID":"10","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | MedProve"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"VIETNAM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Darbepoetin alfa","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase III","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve","highestDevelopmentStatusID":"10","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"Nanocovax","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"Nanocovax","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Inapplicable"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Vietstar Biomedical Research | MedProve","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"VIETNAM","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Trastazumab","moa":"HER2","graph1":"Oncology","graph2":"Phase III","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | MedProve","highestDevelopmentStatusID":"10","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | MedProve"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"VIETNAM","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Darbepoetin alfa","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting","highestDevelopmentStatusID":"6","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting"},{"orgOrder":0,"company":"Nanogen Pharmaceutical Biotechnology","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"VIETNAM","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Erythropoietin Alfa","moa":"EPO receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Nanogen Pharmaceutical Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nanogen Pharmaceutical Biotechnology \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nanogen Pharmaceutical Biotechnology \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Nanogen Pharmaceutical Biotechnology

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          April 10, 2025

                          Lead Product(s) : Peginterferon Alfa-2a

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          April 09, 2025

                          Lead Product(s) : Erythropoietin Alfa

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Lead Product(s) : Darbepoetin alfa

                          Therapeutic Area : Nephrology

                          Study Phase : Phase I

                          Sponsor : Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 05, 2022

                          Lead Product(s) : Darbepoetin alfa

                          Therapeutic Area : Nephrology

                          Highest Development Status : Phase I

                          Sponsor : Vietstar Biomedical Research | Clinical Research Consultants, Inc. | Clinical Research Viet Nam Skill Training And Consulting

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Lead Product(s) : Darbepoetin alfa

                          Therapeutic Area : Hematology

                          Study Phase : Phase III

                          Sponsor : Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : NNG-DEPO

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 19, 2022

                          Lead Product(s) : Darbepoetin alfa

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Sponsor : Vietstar Biomedical Research | Medphase Clinical Research Consultant Company Ltd | Clinical Research Viet Nam Skill Training And Consulting | MedProve

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Faceptor

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 29, 2022

                          Lead Product(s) : Trastazumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Vietstar Biomedical Research | MedProve

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Faceptor

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          March 29, 2022

                          Lead Product(s) : Trastazumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Vietstar Biomedical Research | MedProve

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          CPHI Shenzhen
                          Not Confirmed
                          CPHI Shenzhen
                          Not Confirmed

                          Details : THSTI has entered into a research collaboration with Nanogen Pharmaceutical, which is developing a new vaccine for COVID-19 named Nano Covax which is the first Covid-19 vaccine to be approved by Vietnam’s Ministry of Health to conduct clinical trial in...

                          Product Name : Nanocovax

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          September 27, 2021

                          Lead Product(s) : Nanocovax

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Recipient : The Translational Health Science and Technology Institute

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          June 11, 2021

                          Lead Product(s) : Nanocovax

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          December 24, 2020

                          Lead Product(s) : Nanocovax

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmaconex
                          Not Confirmed
                          Pharmaconex
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Pegcyte

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          December 22, 2017

                          Lead Product(s) : Pegfilgrastim

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank